Labcorp Holdings Inc. $LH Shares Sold by American Century Companies Inc.

American Century Companies Inc. trimmed its position in Labcorp Holdings Inc. (NYSE:LH) by 14.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 766,432 shares of the medical research company’s stock after selling 128,419 shares during the quarter. American Century Companies Inc. owned 0.92% of Labcorp worth $220,012,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. SP Asset Management LLC increased its position in Labcorp by 0.3% during the 2nd quarter. SP Asset Management LLC now owns 14,177 shares of the medical research company’s stock worth $3,722,000 after purchasing an additional 38 shares in the last quarter. HBK Sorce Advisory LLC increased its position in shares of Labcorp by 4.3% in the third quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock worth $254,000 after acquiring an additional 38 shares in the last quarter. Pure Financial Advisors LLC raised its stake in shares of Labcorp by 3.9% in the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock valued at $292,000 after acquiring an additional 38 shares during the period. Zions Bancorporation National Association UT lifted its holdings in shares of Labcorp by 21.9% during the 2nd quarter. Zions Bancorporation National Association UT now owns 223 shares of the medical research company’s stock valued at $59,000 after acquiring an additional 40 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its holdings in shares of Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Stock Performance

Labcorp stock opened at $288.92 on Friday. Labcorp Holdings Inc. has a 52 week low of $209.38 and a 52 week high of $293.72. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The stock has a market cap of $23.81 billion, a P/E ratio of 27.62, a price-to-earnings-growth ratio of 1.97 and a beta of 1.03. The stock has a 50 day moving average of $268.50 and a 200-day moving average of $270.01.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm had revenue of $3.52 billion for the quarter, compared to analysts’ expectations of $3.56 billion. During the same period in the prior year, the company posted $3.45 earnings per share. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, analysts expect that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is presently 27.53%.

Insider Buying and Selling

In related news, CEO Adam H. Schechter sold 5,273 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total value of $1,499,535.74. Following the completion of the sale, the chief executive officer directly owned 87,343 shares of the company’s stock, valued at $24,838,602.34. The trade was a 5.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jonathan C. Meltzer sold 87 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president directly owned 2,782 shares in the company, valued at approximately $807,948.44. This represents a 3.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 6,860 shares of company stock worth $1,954,267. Corporate insiders own 0.84% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the subject of several recent research reports. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Robert W. Baird raised their target price on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $304.42.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.